- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-established and reliably predictive model known as the Revised International Non-Hodgkin's Lymphoma Prognostic Index (IPI or R-IPI). In order for this to be applicable, the patient must have been diagnosed with DLBCL and be treated with Rituximab-based combination chemotherapy, namely R-CHOP.
The Index uses five factors for a prognosis, assigns a single point to each factor if true, then takes the sum total and uses it to determine a survival rate percentage.
This index has shown to be a reasonably predictive model in determining a prognosis; however, it will not hold true for every single diagnosed and treated patient.